Whistleblower Advisor

Since the beginning of time there have been whistleblowers. The trend of whistleblowing has not escaped employees in the corporate world. Therefore, in recent history different organizations have begun to provide whistleblower protection.

What is this whistleblowers protection, you might ask?

Previously a whistleblower had to worry that doing the right thing would cost them their job. There was no set of whistleblower statutes or rights for someone who could not sit by and watch their company commit wrongdoings that broke the law.

If they could not be protected they might now bring these issues to light. In light of this the U.S. Government established the Whistleblowers Protection Act. This protects the whistleblower in many areas, none more important than …

By Jayne O’Donnell, USA TODAY

Seven years ago, David Franklin sued his former employer, Warner-Lambert, for illegally marketing an epilepsy drug for unapproved uses. Little did he know how much that whistleblower lawsuit would unsettle his life.

The microbiologist ended up blackballed in the pharmaceutical industry and had to endure an emotionally and financially draining odyssey as a whistleblower.

“This has been the most disruptive thing that could ever take place …

May 13 (Bloomberg) — Pfizer Inc., the world’s largest drugmaker, agreed to pay at least $400 million to settle civil charges after a whistleblower alleged that Parke-Davis paid kickbacks to encourage doctors to prescribe the epilepsy drug Neurontin for other ailments, people familiar with the case said.

The settlement stems from a U.S. investigation of collusion among drug companies and doctors to bill government health programs for free samples given as promotions. AstraZeneca Plc and Tap Pharmaceuticals Inc. pleaded guilty to criminal charges and agreed to settlements totaling more than $1.2 billion.

“The cost, while seeming to be a lot, probably is worth it to get this issue out of the way,” said Ira Loss, a health-policy analyst at Washington Analysis, which advises institutional investors on federal policy. “Pfizer doesn’t want to have a trial about this, and I don’t think any other major company would either. It’s just easier to pay it off and move on.”

Pfizer, which acquired Parke-Davis when it bought Warner- Lambert Co. for about $120 billion in June 2000, said in a regulatory filing in March it set aside $427 million in the fourth quarter in connection with efforts to …